CXCL12 and cancer: BRCA1 deficiency activates S100A9-CXCL12 signaling for cancer progression and triggers the expansion and accumulation of myeloid-derived suppressor cells, creating a tumor-permissive microenvironment and rendering cancers insensitive to immune checkpoint inhibitors (74).